RemeGen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 3,146

Employees

  • Stock Symbol
  • 09995

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $8.50
  • (As of Friday Closing)

RemeGen General Information

Description

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.

Contact Information

Website
www.remegen.cn
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 58 Beijing Middle Road, Yantai Development Zone, Yantai Area
  • China (China) Pilot Free Trade Zone
  • Yantai, Shandong 264006
  • China
+86 0535
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Number 58 Beijing Middle Road, Yantai Development Zone, Yantai Area
  • China (China) Pilot Free Trade Zone
  • Yantai, Shandong 264006
  • China
+86 0535

RemeGen Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RemeGen Stock Performance

As of 13-Nov-2026, RemeGen’s stock price is $8.50. Its current market cap is $6.89B with 564M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.50 $8.84 $7.66 - $15.72 $6.89B 564M 2.39M $1.49

RemeGen Financials Summary

As of 30-Jun-2026, RemeGen has a trailing 12-month revenue of $1.14B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,757,414 5,959,317 2,024,806 4,004,574
Revenue 1,143,257 450,760 238,333 152,106
EBITDA 877,993 152,357 (154,083) (180,357)
Net Income 831,957 98,681 (204,637) (213,605)
Total Assets 1,449,340 1,035,927 753,211 779,878
Total Debt 45,776 314,678 365,818 177,748
Public Fundamental Data provided by Morningstar, Inc. disclaimer

RemeGen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore RemeGen‘s full profile, request access.

Request a free trial

RemeGen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceutical
Drug Discovery
Yantai, China
3,146 As of 2026

Beijing, China
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RemeGen Competitors (75)

One of RemeGen’s 75 competitors is Innocare, a Formerly VC-backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Innocare Formerly VC-backed Beijing, China
Mersana Therapeutics Formerly VC-backed Cambridge, MA
Celldex Formerly VC-backed Hampton, NJ
Astellas Pharma Corporation Tokyo, Japan
Connect Biopharmaceuticals Formerly VC-backed Taicang, China
You’re viewing 5 of 75 competitors. Get the full list »

RemeGen Patents

RemeGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026184099-A1 Camptothecin compound and use thereof Pending 03-Mar-2025
WO-2026158443-A1 Method for treating non-small cell lung cancer using anti-pd-1 and vegf bispecific antibody Pending 23-Jan-2025
WO-2026052046-A1 Use of anti-claudin 18.2 antibody-drug conjugate for treating gastric cancer and/or gastroesophageal junction adenocarcinoma Pending 06-Sep-2024
WO-2026025013-A3 Combination therapies using cdk4 inhibitors and anti-her2 therapeutic agents for use in the treatment of cancer Pending 26-Jul-2024
WO-2026025013-A2 Combination therapy using cdk4 inhibitors for cancer treatments Pending 26-Jul-2024 A61K31/506
To view RemeGen’s complete patent history, request access »

RemeGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RemeGen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore RemeGen‘s full profile, request access.

Request a free trial

RemeGen Investments (4)

RemeGen’s most recent deal was a IPO with ImmuneOnco for . The deal was made on 05-Sep-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ImmuneOnco 05-Sep-2023 IPO Drug Discovery
Biocytogen Pharmaceuticals (Beijing) Co 01-Sep-2022 IPO Pharmaceuticals
MabPlex 01-Nov-2018 Later Stage VC Other Pharmaceuticals and Biotechnology
MabPlex 25-Jun-2013 Joint Venture Other Pharmaceuticals and Biotechnology
To view RemeGen’s complete investments history, request access »

RemeGen ESG

Risk Overview

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view RemeGen’s complete esg history, request access »

RemeGen Exits (1)

RemeGen’s most recent exit was on 01-Sep-2022 from Biocytogen Pharmaceuticals (Beijing) Co. The exit was categorized as with 3 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Biocytogen Pharmaceuticals (Beijing) Co 01-Sep-2022 Completed
  • 3 buyers
To view RemeGen’s complete exits history, request access »

RemeGen FAQs

  • When was RemeGen founded?

    RemeGen was founded in 2008.

  • Where is RemeGen headquartered?

    RemeGen is headquartered in Yantai, China.

  • What is the size of RemeGen?

    RemeGen has 3,146 total employees.

  • What industry is RemeGen in?

    RemeGen’s primary industry is Drug Discovery.

  • Is RemeGen a private or public company?

    RemeGen is a Public company.

  • What is RemeGen’s stock symbol?

    The ticker symbol for RemeGen is 09995.

  • What is the current stock price of RemeGen?

    As of 13-Nov-2026 the stock price of RemeGen is $8.50.

  • What is the current market cap of RemeGen?

    The current market capitalization of RemeGen is $6.89B.

  • What is RemeGen’s current revenue?

    The trailing twelve month revenue for RemeGen is $1.14B.

  • Who are RemeGen’s competitors?

    Innocare, Mersana Therapeutics, Celldex, Astellas Pharma, and Connect Biopharmaceuticals are some of the 75 competitors of RemeGen.

  • What is RemeGen’s annual earnings per share (EPS)?

    RemeGen’s EPS for 12 months was $1.49.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process